Advertisement

Vulvar Disease pp 309-312 | Cite as

Hidradenitis Suppurativa

  • Jacob Bornstein
Chapter

Abstract

Hidradenitis suppurativa (HS) is a chronic, follicular occlusive, inflammatory skin condition. It affects the intertriginous skin areas of the axillary, groin, perianal, perineal, and inframammary regions. It presents as recurrent, inflamed nodules and abscesses, draining sinus tracts and bands of severe scar formation. It is associated with pain, bad odor, discharge, and disfigurement. Severity of the disease is staged clinically according to the Hurley staging system. Treatment should include avoidance of trauma to the skin, discontinuation of smoking, and losing weight. The affected region should be washed by antiseptics. In addition, pain should be managed; topical clindamycin cream and topical resorcinol may be applied. Other treatments are intralesional corticosteroid injections and oral tetracyclines. Systemic glucocorticoids, cyclosporine, or the TNF-alpha inhibitors—adalimumab and infliximab—are sometimes tried. In severe cases cold knife or CO2 laser excision of lesions may be used to unroof the lesions, nodules, or sinuses. Wide excision is appropriate for advanced disease. Extensive excisions with skin grafts are also used.

References

  1. 1.
    Sellheyer K, Krahl D. “Hidradenitis suppurativa” is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol. 2005;44:535.CrossRefGoogle Scholar
  2. 2.
    Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. 2016;232:687.CrossRefGoogle Scholar
  3. 3.
    Garg A, Kirby JS, Lavian J, et al. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153:760.CrossRefGoogle Scholar
  4. 4.
    von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2000;14:389.CrossRefGoogle Scholar
  5. 5.
    Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol. 2016;74:1153.CrossRefGoogle Scholar
  6. 6.
    Riis PT, Vinding GR, Ring HC, Jemec GB. Disutility in patients with hidradenitis suppurativa: a cross-sectional study using EuroQoL-5D. Acta Derm Venereol. 2016;96:222.CrossRefGoogle Scholar
  7. 7.
    Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, editors. Dermatologic surgery. New York: Marcel Dekker; 1989. p. 729.Google Scholar
  8. 8.
    von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164:367.CrossRefGoogle Scholar
  9. 9.
    Danby FW, Margesson LJ. Hidradenitis suppurativa. Dermatol Clin. 2010;28:779.CrossRefGoogle Scholar
  10. 10.
    Shuja F, Chan CS, Rosen T. Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review. Dermatol Clin. 2010;28:511.CrossRefGoogle Scholar
  11. 11.
    Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174:839.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Jacob Bornstein
    • 1
  1. 1.Department of Obstetrics and Gynecology Galilee Medical Center, Bar-Ilan University Faculty of MedicineNahariyaIsrael

Personalised recommendations